OS Therapies reports strong survival data for bone cancer treatment

<?xml encoding="utf-8" ?> OS Therapies, Inc. OSTX on Tuesday released interim three-year overall survival data from its ...

OS Therapies: OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance

Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development adviso ...
Yahoo Finance

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully ...

New York, New York--(Newsfile Corp. - October 10, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate ...
Yahoo Finance

OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary ...

New York, New York--(Newsfile Corp. - October 17, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate ...
News Medical

Restoring ADAR2 enzyme reduces metastatic spread in osteosarcoma

Osteosarcoma is the most common primary bone cancer in children, adolescents, and young adults. Although chemotherapy and surgery have improved survival for localized disease, outcomes remain poor ...
Cure Today

Osteosarcoma Guide: Stages, Treatment, Side Effects and Patient Journey

Osteosarcoma primarily affects long bones in teenagers and young adults, requiring early diagnosis for effective treatment. Treatment strategies vary by stage, with surgery and chemotherapy as primary ...